Status:

RECRUITING

Remote Sputum Collection in Cystic Fibrosis

Lead Sponsor:

University of Pennsylvania

Collaborating Sponsors:

Cystic Fibrosis Foundation

Conditions:

Cystic Fibrosis

Infections

Eligibility:

All Genders

18+ years

Brief Summary

Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more chall...

Detailed Description

The clinical standard of care of people with CF is conducting sputum culture for infection surveillance and detection. However, the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) and adoption ...

Eligibility Criteria

Inclusion

  • People with a diagnosis of cystic fibrosis (CF) based on CF Foundation (CFF) guidelines. The CFF guidelines consider a diagnosis of CF based on: (1) two known disease-causing CFTR mutations (based on historical genetic testing in clinical documentation or PortCF, the CFF patient registry), OR (2) sweat chloride 60 mmol/L (based on historical sweat chloride testing in clinical documentation or PortCF) and phenotypic findings consistent with cystic fibrosis in more than one organ system, OR (3) CFF accredited center physician diagnosis, based on clinical manifestations in the absence of two CFTR mutations with full gene mapping (based on historical genetic testing in clinical documentation or PortCF).
  • Age 18 years old or greater
  • People with the ability to comply with study visits and study procedures as judged by the investigator.

Exclusion

  • Solid organ transplant recipients, given the presence of immunosuppression.
  • Those who are unable to tolerate sputum induction (hypertonic saline) or the inability to attempt sputum expectoration.
  • Subjects who do not have access to a FedEx location or pick-up services will be excluded.

Key Trial Info

Start Date :

January 15 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2028

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06950892

Start Date

January 15 2025

End Date

June 30 2028

Last Update

October 1 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

National Jewish Health

Denver, Colorado, United States, 80206

2

Johns Hopkins University

Baltimore, Maryland, United States, 21287

3

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104